Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | THRB | P10828 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | ACR | P10323 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9817644 | 0.92 | MAPT (0.60) | MAPTTHRBSMN1; SMN2TP53KMT2A | |
| SCHEMBL9271331 | 0.87 | MAPT (0.49) | MAPTTHRBSMN1; SMN2TP53KMT2A | |
| SCHEMBL9817392 | 0.87 | MAPT (0.67) | MAPTTHRBSMN1; SMN2TP53KMT2A | |
| SCHEMBL9817427 | 0.86 | MAPT (0.60) | MAPTTHRBSMN1; SMN2TP53KMT2A | |
| SCHEMBL9817679 | 0.85 | RARB (0.60) | MAPTTHRBSMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL9817707 | 0.85 | RARB (0.60) | MAPTTHRBSMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL9817377 | 0.85 | RARB (0.60) | MAPTTHRBSMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL9817417 | 0.85 | RARB (0.60) | MAPTTHRBSMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL9817530 | 0.85 | RARB (0.60) | MAPTTHRBSMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL9817597 | 0.85 | RARB (0.60) | MAPTTHRBSMN1; SMN2KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621958-B1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2024-07-10 | — | — | EP | disclosed |
| EP-3268375-B1 | PHOTOCHROMIC THIENOCHROMENE COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3071576-B9 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3071576-B1 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | TRANSITIONS OPTICAL, LTD. (IE) | 2020-02-13 | — | — | US | disclosed |
| EP-2370420-B9 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-2370420-B1 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3071550-B1 | METHOD OF PREPARING FUSED RING INDENO COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10005763-B2 | Photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005763-B2 | Photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20080096048-A1 | Thermally reversible; absorption ratio greater than 2.3 | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096049-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096049-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096048-A1 | Thermally reversible; absorption ratio greater than 2.3 | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7342112-B2 | Photochromic compounds | PPG INDUSTRIES OHIO, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342112-B2 | Photochromic compounds | PPG INDUSTRIES OHIO, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-20080051575-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL ,INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051575-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL ,INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080045704-A1 | Thermally reversible; absorption ratio greater than 2.3; cell method | TRANSITIONS OPTICAL, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045704-A1 | Thermally reversible; absorption ratio greater than 2.3; cell method | TRANSITIONS OPTICAL, INC. (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | ALDH1A2, RB1, INCENP | MAPT 1822/4885THRB 4353/4885SMN1; SMN2 4769/4885 |
| US-20080045704-A1 | Thermally reversible; absorption ratio greater than 2.3; cell method | CCND3, CCND1, CCND2 | MAPT 4145/4885THRB 2453/4885SMN1; SMN2 1316/4885 |
| US-20080096048-A1 | Thermally reversible; absorption ratio greater than 2.3 | CCND1, CCND3, CCND2 | MAPT 4150/4885THRB 2576/4885SMN1; SMN2 1502/4885 |
| US-10005763-B2 | Photochromic compounds | CCR4, CCR8, CBR3 | MAPT 3402/4885THRB 1098/4885SMN1; SMN2 4001/4885 |
| US-20080051575-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | CCND1, CCND2, CCNE1 | MAPT 4085/4885THRB 1288/4885SMN1; SMN2 993/4885 |
| US-20080096049-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | CCND1, CCND2, CCNE1 | MAPT 4085/4885THRB 1288/4885SMN1; SMN2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.